Catabasis Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 8, 2018--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2018 Wedbush PacGrow Healthcare Conference on Wednesday, August 15, 2018 at 2:30pm ET at the Le Parker Meridien Hotel in New York, NY.
A webcast of the presentation will be available in the Investors section of the Company’s website, www.catabasis.com, and will be archived for 30 days following the presentation.
About Catabasis At Catabasis Pharmaceuticals, our mission is to bring hope and life-changing therapies to patients and their families. Our lead program is edasalonexent, an NF-kB inhibitor in development for the treatment of Duchenne muscular dystrophy. The global Phase 3 POLARIS DMD trial is expected to initiate in the second half of 2018. For more information on edasalonexent and our Phase 3 POLARIS DMD trial, please visit www.catabasis.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180808005022/en/
CONTACT: Investor and Media Contact
Catabasis Pharmaceuticals, Inc.
Andrea Matthews, 617-349-1971
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Catabasis Pharmaceuticals, Inc.
Copyright Business Wire 2018.
PUB: 08/08/2018 08:00 AM/DISC: 08/08/2018 08:01 AM